Clinical Trials
11
Active:1
Completed:4
Trial Phases
3 Phases
Phase 1:5
Phase 2:4
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (45.5%)Phase 2
4 (36.4%)Phase 3
2 (18.2%)Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC
Phase 3
Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Drug: Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injectionDrug: placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection
- First Posted Date
- 2023-11-09
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
- Target Recruit Count
- 390
- Registration Number
- NCT06123754
- Locations
- 🇨🇳
Tianjin cancer hospital, Tianjing, Tianjin, China
Phase I Trial of Envafolimab for Healthy Male Subjects
Phase 1
Completed
- Conditions
- Healthy Male
- Interventions
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
- Target Recruit Count
- 160
- Registration Number
- NCT05849311
- Locations
- 🇨🇳
Beijing Gaobo Boren Hosipital, Beijing, Beijing, China
Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer
Phase 2
Recruiting
- Conditions
- Advanced Endometrial Cancer
- Interventions
- Drug: Envafolimab+Lenvatinib
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
- Target Recruit Count
- 108
- Registration Number
- NCT05112991
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Chongqing University Three Gorges Hospital, Chongqing, Chongqing, China
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
Phase 1
Recruiting
- Conditions
- Solid TumorsRenal Cell CarcinomaNon-small Cell Lung CancerHepatocellular Carcinoma
- Interventions
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
- Target Recruit Count
- 170
- Registration Number
- NCT05024214
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Benbu, Anhui, China
🇨🇳The Seventh Medical Center of the PLA General Hospital, Beijing, Beijing, China
🇨🇳Beijing Hospital, Beijing, Beijing, China
Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers
Phase 2
Not yet recruiting
- Conditions
- Biliary Tract Neoplasms
- Interventions
- Drug: Gemcitabine&Cisplatin
- First Posted Date
- 2021-06-02
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
- Target Recruit Count
- 126
- Registration Number
- NCT04910386
- Prev
- 1
- 2
- 3
- Next
News
No news found